The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer

Journal of Gastrointestinal Oncology

Hiroshi Nakano²  Sumito Sato¹  Takehito Otsubo²  Yasuo Ishida¹ 

[1] Department of Surgery, Yokohama Asahi Central and General Hospital, 4-20-1 Wakabadai Asahi-ku Yokohama, 241-0801 Kanagawa, JapanDepartment of Surgery, Yokohama Asahi Central and General Hospital, 4-20-1 Wakabadai Asahi-ku Yokohama, 241-0801 Kanagawa, JapanDepartment of Surgery, Yokohama Asahi Central and General Hospital, 4-20-1 Wakabadai Asahi-ku Yokohama, 241-0801 Kanagawa, Japan;Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine Hospital, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Kanagawa, Japan Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine Hospital, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Kanagawa, Japan Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine Hospital, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Kanagawa, Japan

关键词: Aspartate aminotransferase;    platelet;    splenomegaly;    chemotherapy;    colorectal cancer;   

DOI  :  10.3978/j.issn.2078-6891.2013.016

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown